Palbociclib is the first marketed cell CDK4/6 inhibitor that exerts its antitumor effects by inhibiting the binding of CDK4/6 and cell cycle protein D, interfering with retinoblastoma protein (RB) phosphorylation, and reducing cell proliferation in breast cancer cell lines (4). This evidence concerns the gene CDK4 and breast carcinoma.